Cognitive & Sleep Peptides: Semax, DSIP and the Evidence (2026)

The peptides marketed for the brain split into two jobs — sharper days and better nights — and the molecules behind them rarely overlap. Semax sits on the cognition side, DSIP on the sleep side, and Epitalon shows up because its FDA indication under review is insomnia. All three are real research peptides, and none has human evidence that it works. Here is the sourced 2026 picture.

What are cognitive peptides?

The label covers research peptides studied around the central nervous system: attention, memory, neuroprotection, and the sleep that underwrites all of them. The most-searched are Semax, an ACTH(4-7) analog studied for cognitive and neuroprotective effects, and DSIP, the delta sleep-inducing peptide studied around sleep onset and stress. Epitalon, a pineal tetrapeptide, enters the same conversation through sleep — insomnia is its evaluated FDA indication. They are a class, not a single thing, which is why head-to-head searches mostly compare different jobs.

Semax: the cognition side

Semax is the molecule people mean when they say “nootropic peptide.” The research is on neuroprotection and cognition, including cerebral-ischemia models, and it is all preclinical — no registered human trial, no published randomized controlled trial in the major registries as of June 2026. The indexed record is on the Semax evidence and regulatory page. For how it stacks against a sleep peptide, see Semax vs DSIP.

DSIP and Epitalon: the sleep side

DSIP is named for its association with delta-wave sleep and is studied around sleep regulation, stress and withdrawal; Epitalon reaches sleep through circadian biology and carries insomnia as its FDA indication. Both are preclinical with no registered trial. They are reviewed on the same July 24 agenda, which is exactly why they get compared — see Epitalon vs DSIP and, on the cognition crossover, Epitalon vs Semax. The full DSIP record is on the DSIP evidence and regulatory page.

The honest state of the evidence

For how we separate a cell study from an animal study from a human trial, see how we grade peptide evidence. Applied here, every one of these molecules grades at preclinical. Watch out for inflated study counts: short names like DSIP and Semax pull unrelated papers into a database tally, so a “human study” count is not human evidence for the peptide itself. The figure that matters — published human RCTs — is zero across Semax, DSIP and Epitalon.

Regulation: the July 2026 FDA vote

All three were removed from the FDA 503A “do not compound” list in April 2026, which did not make them compoundable. The Pharmacy Compounding Advisory Committee reviews Semax, DSIP and Epitalon on July 24, 2026. We break down the full agenda in the July 2026 FDA peptide meeting, explained. None carries a marketing authorization in the European Union.

The bottom line

Cognitive and sleep peptides are sold on outcomes — focus, recovery, sleep — that no human trial has yet demonstrated for any of them. Semax, DSIP and Epitalon are preclinical research molecules aimed at different targets, not interchangeable brain-boosters. Start from the sourced comparisons above and watch the July 2026 vote for the next real change.

Research information only, not medical advice. None of these peptides is approved for human use. Talk to a licensed physician before considering any peptide.